HSPG2 and acute myeloid leukemia: In this study, the HSPG2 levels and BM EPC's functions were compared between AML patients after CR (CR patients) who received idarubicin and cytarabine (IA) regimen or homoharringtonine, aclarubicin, and cytarabine (HAA) regimen as induction chemotherapy and their age‐matched healthy controls (HCs).